LOGOLOGOLOGOLOGO
    • About us
      • What we do
      • Who we are
        • Governance
        • Staff
        • Vacancies
    • Members
      • EuropaBio Members
      • About Membership
    • How we work
      • Healthcare Biotechnology Council
        • Patient BioForum
        • Study – Impact of the EU’s General Pharmaceutical Legislation
      • Industrial Biotechnology Council
        • EFIB
        • Microorganisms
      • National Associations Council
      • SME Platform
      • Biomanufacturing Platform
        • Biotechnology in our Lives
    • Activities
      • 25 Years of Innovation
      • The EU Biotech Act
      • European Biotech Week
      • EU Projects
        • PRIMED Project
        • APROVALS Project
    • News & Events
      • News
      • Events
    • Library
    Become a member
    ✕

    Healthy Planet, Healthy People: a Pathway for Green Transition in the Biopharmaceutical Ecosystem

    26/10/2021
    NEWS RELEASE
    Healthy Planet, Healthy People: a Pathway for Green Transition in the Biopharmaceutical Ecosystem

    Brussels, 26 October 2021- On the 25th of October, as part of its 25th Anniversary programme, EuropaBio and member Novartis invited the healthcare community and relevant stakeholders to focus on the green transition and how it will shape healthcare for us all.

    Event speakers were:

    • Carmen Laplaza, Head of Unit, Health Innovations and Ecosystems, DG Research and Innovation
    • Montserrat Montaner, Chief Sustainability Officer, Novartis
    • Jutta Paulus, Member of the European Parliament, Group of the Greens, Germany
    • Dr. Wouter De Soete, Manager Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing, University of Ghent
    • Kristin Schreiber, Director, Directorate Ecosystems: Chemicals, Food, Retail, Health, DG Grow, European Commission

    Dr. Claire Skentelbery, Director General, EuropaBio moderated the discussion.

    The event was kicked off with opening comments from Jutta Paulus, MEP, Group of the Greens. Mrs Paulus stressed the importance of better preparedness for the next pandemics and, at the same time, lowering our impact on biodiversity and the environment. According to MEP Paulus, only when we find a more sustainable way to manage wastewater and animals and produce materials, including biopharmaceuticals, can we protect ourselves from further environmental damage.

    Montse Montaner, Chief Sustainability Officer of Novartis continued the discussion, with some key Novartis priorities regarding sustainability of biopharmaceuticals. She stated that Novartis has a goal to minimise impact on the planet, reach carbon neutrality across the value chain by 2030 and become net zero by 2040. Novartis also aims to be water sustainable and plastic neutral by 2030.

    Carmen Laplaza, Head of Unit, Health Innovations and Ecosystems, DG Research and Innovation, pointed out that the tendency of pharmaceutical manufacturing leaving the European Union, creates vulnerabilities in the supply chain which needs to be addressed, not only from the environmental point perspective but also taking into account economic and health related issues. She stated that various EC instruments in the context of Horizon Europe such as collaborative grants, partnerships and missions are addressing these ongoing challenges.

    Wouter De Soete, Manager of the Centre of Excellence in Sustainable Pharmaceutical Engineering & Manufacturing, University of Ghent, highlighted that integrating sustainability aspects early in the biomanufacturing process helps to position sustainability not as a burden but rather as an opportunity for business and innovation. He also stressed the importance of the knowledge triangle, a key ingredient to creating local ecosystems that can attract investments.

    Kristin Schreiber, Director, Directorate Ecosystems: Chemicals, Food, Retail, Health, DG Grow stated that the European Commission is looking at the co-creation process together with industry, public authorities and social partners to establish green and digital pathways for the different ecosystems. She added that the sustainability aspect must be very much in the forefront and include a much better understanding of the cost long-term benefits.

    The event recording is available here.

    Healthy Planet, Healthy People


    Download
    Share
    Communications Team
    Communications Team

    Related posts

    12/05/2026

    ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act


    Read more
    08/05/2026

    Technovative Solutions Ltd. joins EuropaBio: Advancing AI‑Driven and Sustainable Innovation in Biotechnology


    Read more
    23/04/2026

    ITRE’s recognition of the importance of biomanufacturing and of biotechnology as a horizontal enabling technology for Europe’s future in the European Competitiveness Fund


    Read more

    Important links

    • ‘Consistency, cooperation and practicality are the watch words’. EuropaBio reacts to provisional agreement on the Critical Medicines Act
    • Technovative Solutions Ltd. joins EuropaBio: Advancing AI‑Driven and Sustainable Innovation in Biotechnology

    Categories in our Newsroom

    EBIO-white

    EuropaBio represents corporate and associate members across sectors, plus national and regional biotechnology associations which, in turn, represent over 5000 biotech companies, 4600 out of them are SMEs.

    Contact us

    Extra links

    Members
    Staff
    Privacy policy
    Legal & cookies
    Events
    Newsroom

    Become a member

    Media pack

    © 2026 Europabio. All Rights Reserved. Designed by EYAS
    Become a member

    Vitamin B2

    The biomanufacturing of Vitamin B2 led to the reduction of 75% of fossil raw materials and 50% operating costs, compared to the chemical process. Vitamin B2 is used in the food, feed or healthcare sectors.

    Insulin

    Insulin is one of the most widely known biopharmaceutical. Biotechnology revolutionised its manufacturing process and led to the development of new types of insulin through r-DNA technology.

    Detergents

    Enzymes and biosurfactancts are alternative ingredients that improve the performance of detergents, while leading to water and energy savings and reductions in CO2 emissions and water toxicity.

    Clothes

    Clothes made from alternative fibres produced by microorganisms can be 8x stronger than steel, 100% recyclable, biodegradable and replace fossil-fuel based or resource-intensive textiles.

    Algal Omega 3

    Algal Omega-3 is an innovative feed product for aquaculture. It reduces the impact on climate change by 30-40% compared to fish oil and saves 60 tons of wild fish for every ton of Algal Omega-3 used.

    Cheese

    Cheese is a vegetarian product thanks to biotechnology. Biotechnology is also essential to produce lactose- or cholesterol-free cheese, as well as alternative proteins.